亚宝药业：获得《药物临床试验批准通知书》

Group 1 - The core point of the article is that Yabao Pharmaceutical has received approval from the National Medical Products Administration for the clinical trial of GLX002 [1] Group 2 - Yabao Pharmaceutical's wholly-owned subsidiary, Beijing Yabao Biopharmaceutical Co., Ltd., is responsible for the development of GLX002 [1]